Previous 10 | Next 10 |
IceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons' 24th Annual Meeting PR Newswire Physicians Attending the CME Course to Demo ProSense, Learn More About Breast Cryoablation, and Receive Hand...
IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery PR Newswire ProSense System among the two types of systems used in the study Pain-free survival rates of 93.75% at 6 months an...
2023-04-19 08:24:19 ET IceCure Medical ( NASDAQ: ICCM ) said on Wednesday that it has initiated a process to voluntarily delist its shares from the Tel Aviv Stock Exchange. The last day for the shares to trade on TASE will be July 20, and the shares will be delisted from the s...
IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange PR Newswire CAESAREA , Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("...
2023-03-29 13:33:06 ET IceCure Medical Ltd (ICCM) Q4 2023 Earnings Conference Call March 29, 2023 10:00 a.m. ET Company Participants Eyal Shamir - CEO Ronen Tsimerman - CFO & COO Todd Kehrli - EVC Group, IR Conference Call Participants Kemp Dolliv...
2023-03-29 08:07:09 ET IceCure Medical press release ( NASDAQ: ICCM ): FY GAAP EPS of -$0.46 misses by $0.35 . Revenue of $3.1M (-24.4% Y/Y) beats by $2.1M . Gross margin was approximately 47% for the twelve months ended December 31, 2022, compared to approxima...
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to ...
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes PR Newswire This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approve...
IceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023 IceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023 PR Newswire CAESAREA, Israel , March 20, 2023 /PRNewswire/ -- IceCu...
IceCure Medical ( NASDAQ: ICCM ) announced preliminary unaudited revenues of $3.1M in 2022, compared to $4.1M a year earlier, due to decreased revenue recognition of about $0.6M from the distribution agreement with Terumo and a decrease of sales in most territories by 25%. Analy...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...